A Single-Center, Open-Label Trial of Isavuconazole Prophylaxis against Invasive Fungal Infection in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation

Hematopoietic cell transplantation (HCT) is associated with a high risk of invasive fungal infections (IFIs). Fluconazole is approved in the United States for Candida prophylaxis during HCT, but it does not provide coverage against molds [1]. Voriconazole, a broad-spectrum triazole active against Candida and Aspergillus species, has been increasingly used for antifungal prophylaxis in patients undergoing high-risk HCT, such as cord blood HCT and ex vivo T cell-depleted HCT recipients [2-4]. In a randomized trial of voriconazole versus fluconazole prophylaxis in standard-risk HCT recipients, the overall rates of IFI and fungal infection-free survival at 6 and 12 months were similar in the 2 arms, but there was a significant decrease in infections caused by Aspergillus in the voriconazole arm at 6 months [5].

Source: Biology of Blood and Marrow Transplantation - February 19, 2020 Category: Hematology Authors: Anat Stern, Yiqi Su, Yeon Joo Lee, Susan Seo, Brian Shaffer, Roni Tamari, Boglarka Gyurkocza, Juliet Barker, Yael Bogler, Sergio Giralt, Miguel Perales, Genovefa A. Papanicolaou Source Type: research